Governance, Risk, and Accountability For the Next Era of Healthcare AI
AI is no longer waiting for a future budget cycle.
Eliciting Insights’ 2026 AI Adoption Survey found that 75% of U.S. health systems were using or planning to use at least one AI application, up from 58% in 2025. That does not mean every deployment is mature, clinically meaningful or ready to scale. It means AI has already moved from pilot-stage possibility to enterprise reality for many organizations.
The next question is whether governance can move at the same pace. For health system CEOs, AI governance is not simply a technology control. It is the leadership infrastructure that determines whether the organization can scale AI with trust, protect patients, support clinicians and show boards that innovation is being managed responsibly.
AI governance is leadership infrastructure for scaling AI with trust.
Why AI Governance Has Become a CEO Imperative
AI governance became a CEO issue because the risk profile changed.
Early pilots could often be contained inside innovation teams, digital departments or single service lines. Enterprise AI cannot. Once AI touches clinical workflows, patient communication, revenue cycle, staffing, documentation, access or decision support, the implications reach across quality, safety, compliance, finance, workforce trust and reputation.
The external expectations are also becoming clearer. In 2025, The Joint Commission and the Coalition for Health AI released initial guidance to support responsible AI adoption across health systems. The guidance emphasizes policies, local validation, monitoring and responsible use, which moves AI oversight beyond IT and into executive leadership. In 2026, The Joint Commission also introduced a voluntary Responsible Use of AI in Healthcare Certification focused on organizational governance, safeguards, monitoring and education rather than certification of individual AI products.
That does not mean the CEO needs to become a technical expert. It means the CEO needs to know whether the organization can answer basic governance questions with confidence: Which AI tools are in use? Which tools affect clinical decisions or patient experience? Who owns the risk? How are tools validated? What gets escalated when performance drifts? What does the board see, and how often?
If those answers are unclear, the organization is not just facing a technology gap. It is facing an accountability gap.
Five Questions to Bring to the Next AI Governance Discussion
AI governance becomes more practical when leaders know which questions to ask.
These five questions can help CEOs and executive teams assess whether AI oversight is clear, consistent and ready to scale.
Most health systems have more AI in use than leadership realizes, especially when AI is embedded in EHRs, vendor platforms, documentation tools or department-level workflows. A current inventory helps leaders understand where AI is already influencing operations, where risk may be entering quietly and which tools need formal review.
Not every AI tool carries the same level of risk. Tools that shape clinical action, patient experience, reimbursement, workforce decisions or care access need closer oversight because their impact reaches beyond productivity. This question helps leaders separate low-risk administrative use cases from tools that require deeper validation and monitoring.
AI governance breaks down when accountability is unclear. Health systems need defined ownership across clinical, technical, legal, compliance and operational teams before an issue occurs. Clear accountability helps ensure concerns are escalated quickly and decisions are not left to individual departments after deployment.
Vendor testing is not enough on its own. An AI tool may perform differently depending on the health system’s patient population, data quality, EHR configuration and clinical workflow. Local validation helps leaders understand whether a tool is safe, effective and appropriate in their specific operating environment.
Board oversight requires more than occasional updates on AI strategy. Leaders should be able to report which tools are in use, which high-risk tools are under review, what issues have been escalated and whether monitoring shows performance drift, bias or safety concerns. This turns AI governance from a policy statement into a measurable leadership discipline.
What a Mature AI Governance Framework Should Put in Place
The strongest AI governance framework is not a committee that occasionally approves tools.
It is an operating model that defines ownership before deployment, monitors performance after deployment and gives executives a clear view of AI risk across the enterprise.
A practical framework has three layers: governance structure, governance process and governance evidence. Structure determines who owns decisions. Process determines how tools are reviewed, approved and monitored. Evidence determines whether leaders can prove governance is working.
Governance Structure
Health systems need an executive sponsor with cross-functional authority, supported by an AI governance council or clinical advisory board.
That group should include clinical leadership, IT, data, privacy, legal, compliance, quality, patient safety, operations and, where possible, patient advocacy.
Governance also needs a dual accountability model: clinical leaders own patient safety and care impact, while technology leaders own system performance, integration, cybersecurity and data integrity.
Governance Process
AI tools should move through a consistent intake and review process before deployment.
That process should include intended use, risk tiering, privacy and security review, bias assessment, workflow fit, evidence review, local validation requirements, human oversight expectations and post-deployment monitoring plans.
The goal is not to slow every AI use case. The goal is to match oversight to risk.
Governance Evidence
Executives also need documentation.
That includes an AI inventory, approval records, validation summaries, monitoring dashboards, model cards or similar transparency tools, safety reports and board-level reporting.
Without evidence, governance is difficult to audit, difficult to improve and difficult to defend after a problem occurs.
Risk Tiering Keeps Governance Practical
Despite its potential, AI adoption in healthcare is not without friction.
In many cases, implementation challenges—not the technology itself—determine whether AI initiatives succeed or stall.
Not every AI tool requires the same level of scrutiny. A chatbot that helps staff summarize internal policy documents does not carry the same risk as a diagnostic support tool or an AI-enabled medical device. A mature AI governance framework should recognize that difference.
A practical risk-tiering model might look like this:
- Lower-risk use cases: internal administrative support, meeting summaries, nonclinical drafting, operational reporting and workflow assistance where humans review outputs before action.
- Moderate-risk use cases: patient-facing chatbots, scheduling or access navigation, clinical documentation support, revenue cycle prioritization and tools that may affect patient experience or operational decisions.
- Higher-risk use cases: clinical decision support, diagnostic assistance, treatment recommendations, deterioration prediction, AI-enabled medical devices and tools that directly influence clinical action or patient safety.
Risk tiering helps CEOs avoid two common failures: over-governing low-risk tools until innovation stalls, and under-governing high-risk tools until the organization is exposed. The discipline is knowing which tools require deeper validation, which can move through a lighter pathway and which should not be deployed until stronger evidence exists.
Bias, Validation and Safety Reporting Are the Core Obligations
Three obligations should sit at the center of health system AI governance.
This includes: local validation, bias assessment and safety reporting. They are not the only responsibilities, but they are the ones most directly connected to trust.
Local validation comes first.
Vendor evidence can help, but it cannot answer every implementation question. A tool that performs well in one setting may perform differently in another patient population, EHR environment, clinical workflow or staffing model. The Joint Commission and CHAI guidance points to local validation and ongoing monitoring as part of responsible AI use.
Bias assessment is equally important.
Health systems need to know whether an AI tool performs consistently across the populations they serve. That means asking whether the data used to train or validate the tool was representative, whether subgroup performance has been assessed and whether outcomes are monitored after deployment. For CEOs and boards, algorithmic bias is not a technical footnote. It is a quality, equity, reputational and patient trust issue.
Safety reporting must also be integrated into existing structures.
AI-related adverse events, near misses, clinician concerns and unexpected performance changes should flow through patient safety, quality and risk channels, including sentinel event workflows when applicable. These concerns should not live in an innovation tracker that executives never see.
Tools such as model cards can make this work more consistent.
CHAI has advanced an applied model card concept, often described as an AI “nutrition label,” to help organizations document intended use, limitations, known risks, bias considerations and performance information. Model cards are not a substitute for local validation, but they can make governance reviews more transparent and repeatable.
Vendor Governance Is Where AI Risk Often Enters Quietly
Health systems are not only building AI. They are buying it, inheriting it through EHRs and enterprise platforms, and encountering it inside tools that may not have been marketed as AI products when the original contract was signed.
That makes procurement and vendor management a critical part of AI governance.
Before adopting or expanding an AI-enabled product, health systems should require vendors to explain:
- The intended use of the tool and where it should not be used.
- What data was used to train and validate the model, including known limitations.
- How the tool performs across relevant patient groups and care settings.
- How model updates, retraining or performance changes are communicated.
- What monitoring, audit logs and rollback options are available.
- How patient data is used, stored, protected and potentially reused.
- What human oversight is expected in the workflow.
- Who is responsible when the tool fails, performs differently than expected or changes over time.
For CEOs, the point is not to personally negotiate every AI contract. It is to make sure procurement, legal, compliance, IT and clinical leadership are using the same standard before AI enters the enterprise. Otherwise, the organization may discover too late that a tool was deployed without enough transparency, oversight or contractual protection.
What CEOs Need to Know About the Regulatory Landscape
The regulatory environment is still evolving, but it is not empty. CEOs need a working understanding of what is binding, what is voluntary and what is becoming the practical expectation for responsible AI use.
The Joint Commission and CHAI guidance
is voluntary, but important. It gives healthcare organizations a clearer benchmark for policies, validation, monitoring and responsible use. The newer RUAIH Certification is also voluntary and focuses on the governance and safeguards healthcare organizations have in place, not whether a specific AI product is certified.
ONC’s HTI-1 final rule
is especially relevant for AI and predictive algorithms embedded in certified health IT. ONC describes the rule as establishing first-of-its-kind transparency requirements for AI and other predictive algorithms that are part of certified health IT. For health system leaders, this matters because many AI capabilities will arrive through tools clinicians already use, not through a standalone AI purchase.
FDA oversight
matters when AI is part of a regulated medical device or software as a medical device. In those cases, many FDA obligations sit with the manufacturer or developer, but health systems still need to understand what has been authorized, how the tool is intended to be used, what changes may affect risk and how post-market issues will be monitored. FDA has also issued draft guidance on lifecycle management and marketing submission recommendations for AI-enabled device software functions.
The NIST AI Risk Management Framework
is voluntary, but useful because it gives leaders a shared language for identifying, measuring and managing AI risk. For health systems, it can help legal, compliance, technology and clinical teams align around a common risk management approach.
The EU AI Act
may also influence how AI tools are classified, documented and governed for health systems with international operations or global vendor relationships,. That does not need to dominate the agenda for every U.S. health system, but it should be on the radar for organizations operating across markets.
The leadership takeaway is clear: healthcare AI governance cannot be built around one rule, one department or one annual review. It has to be durable enough to adapt as standards, certification programs, regulations and vendor capabilities continue to change.
From Risk Control to Strategic Advantage
AI governance is often framed as risk control. That is accurate, but incomplete.
Governance is also what allows a health system to move faster with more confidence.
Without governance, AI adoption becomes fragmented. Different departments may buy overlapping tools. Clinicians may lose trust in outputs that are poorly integrated or insufficiently explained. Legal and compliance teams may get pulled in only after a problem surfaces. Boards may hear about AI strategy without seeing the controls behind it.
With governance, leaders can make better decisions about which AI use cases are ready to scale, which require more evidence and which should be stopped. They can also set clearer expectations for vendors, strengthen clinician confidence and demonstrate to patients, boards and regulators that AI is being used with discipline.
That creates competitive advantage. Health systems that can responsibly scale AI will be better positioned to improve workflows, reduce administrative burden, support care quality and strengthen trust. Those that deploy AI without governance may appear to move quickly, but speed without control is not transformation. It is exposure.
What HIMSS27 Adds for Health System Leaders
HIMSS27, taking place April 5-8, 2027, at McCormick Place in Chicago, will bring health system leaders together at a moment when AI governance is becoming a defining leadership issue.
The value is not simply seeing what AI can do. It is understanding how organizations are governing it, scaling it, measuring it and earning the trust to use it responsibly.
For CEOs, CMOs, CNOs, CIOs and board-level leaders, the HIMSS27 Executive Summit will offer a focused environment for strategic conversations about digital transformation, leadership accountability, risk management and enterprise change.
The broader HIMSS27 experience can also help executives pressure-test vendor claims, compare governance models, understand emerging expectations and evaluate how peers are translating frameworks into operational practice. As the agenda develops, leaders can use the session program to identify AI governance, risk, strategy and implementation discussions relevant to their teams.
AI Governance Is Now Leadership Infrastructure
AI governance is no longer a side project for IT. It is leadership infrastructure for any health system planning to use AI at scale.
The frameworks are becoming clearer. The expectations are rising. The risks are too visible to ignore. For every health system CEO, the question is not whether AI governance belongs on the executive agenda. It is whether the organization is building it quickly enough and seriously enough to earn the trust required to scale AI responsibly.